CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes

[1]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[2]  V Goh,et al.  Assessment of changes in tumor heterogeneity following neoadjuvant chemotherapy in primary esophageal cancer. , 2015, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[3]  A. Degnim,et al.  A multivariate model to predict cancer upgrade from atypical ductal hyperplasia by core needle biopsy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Hartmut Link,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[5]  E. Van Cutsem,et al.  Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  R. Korn,et al.  Noninvasive Image Texture Analysis Differentiates K-ras Mutation from Pan-Wildtype NSCLC and Is Prognostic , 2014, PloS one.

[7]  R. Schilsky,et al.  CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Peter J. Ell,et al.  Multifunctional Imaging Signature for V-KI-RAS2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations in Colorectal Cancer , 2014, The Journal of Nuclear Medicine.

[9]  Aaron D Ward,et al.  Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer. , 2014, Medical physics.

[10]  Jae-Hun Kim,et al.  Quantitative CT Variables Enabling Response Prediction in Neoadjuvant Therapy with EGFR-TKIs: Are They Different from Those in Neoadjuvant Concurrent Chemoradiotherapy? , 2014, PloS one.

[11]  V. Goh,et al.  Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy. , 2013, Radiology.

[12]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[13]  S. Hendren,et al.  Patient navigation improves the care experience for patients with newly diagnosed cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Michael E Griswold,et al.  Locally advanced squamous cell carcinoma of the head and neck: CT texture and histogram analysis allow independent prediction of overall survival in patients treated with induction chemotherapy. , 2013, Radiology.

[15]  R. Parks,et al.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. , 2013, The Lancet. Oncology.

[16]  Dina Muin,et al.  Texture-based classification of different gastric tumors at contrast-enhanced CT. , 2013, European journal of radiology.

[17]  M. P. Hayball,et al.  CT texture analysis using the filtration-histogram method: what do the measurements mean? , 2013, Cancer imaging : the official publication of the International Cancer Imaging Society.

[18]  Balaji Ganeshan,et al.  Quantifying tumour heterogeneity with CT , 2013, Cancer imaging : the official publication of the International Cancer Imaging Society.

[19]  Vicky Goh,et al.  Assessment of tumor heterogeneity by CT texture analysis: can the largest cross-sectional area be used as an alternative to whole tumor analysis? , 2013, European journal of radiology.

[20]  V. Goh,et al.  Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. , 2013, Radiology.

[21]  V. Goh,et al.  Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. , 2013, Radiology.

[22]  V. Goh,et al.  Quantitative Imaging Biomarkers from PET-CT as potential correlates for angiogenesis and hypoxia in colorectal cancer , 2012 .

[23]  K. Miles,et al.  Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. , 2012, Clinical radiology.

[24]  S. Küry,et al.  Delineation of the infrequent mosaicism of KRAS mutational status in metastatic colorectal adenocarcinomas , 2012, Journal of Clinical Pathology.

[25]  K. Miles,et al.  Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival , 2012, European Radiology.

[26]  V. Goh,et al.  Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. , 2011, Radiology.

[27]  Yoko Yamamoto,et al.  Heterogeneity of KRAS Status May Explain the Subset of Discordant KRAS Status Between Primary and Metastatic Colorectal Cancer , 2011, Diseases of the colon and rectum.

[28]  M Buyse,et al.  Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. , 2011, European journal of cancer.

[29]  P. Quirke,et al.  Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing , 2011, Analytical cellular pathology.

[30]  Balaji Ganeshan,et al.  Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage , 2010, Cancer imaging : the official publication of the International Cancer Imaging Society.

[31]  Chris R Chatwin,et al.  Texture analysis in non-contrast enhanced CT: impact of malignancy on texture in apparently disease-free areas of the liver. , 2009, European journal of radiology.

[32]  Balaji Ganeshan,et al.  Colorectal cancer: texture analysis of portal phase hepatic CT images as a potential marker of survival. , 2009, Radiology.

[33]  Bruce D Minsky,et al.  Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.